Defining risks of taxane neuropathy: Insights from randomized clinical trials

Clinical Cancer Research

Volumn 19, Issue 17, 2013, Pages 4570-4577

  Kudlowitz, David ^a   Muggia, Franco ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; IXABEPILONE; PACLITAXEL; TAXANE DERIVATIVE;

AGE; AXONAL INJURY; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; DISEASE PREDISPOSITION; DOSAGE SCHEDULE COMPARISON; DRUG BIOAVAILABILITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; DRUG TARGETING; ETHNICITY; FEBRILE NEUTROPENIA; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; OPTIMAL DRUG DOSE; OVARY CANCER; PHARMACOGENOMICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SENSORY NEUROPATHY; SEX;

AXONS; BRIDGED COMPOUNDS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; NANOPARTICLES; NEOPLASMS; PACLITAXEL; PERIPHERAL NERVOUS SYSTEM DISEASES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TAXOIDS;

EID: 84883483886     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-0572     Document Type: Review

References (77)

1. Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD, Gianni L, Myles J, van der Burg ME, et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol 1994;12:2654-66. (Pubitemid 24379653)
2. Seidman AD, Hudis CA, Albanel J, Tong W, Tepler I, Currie V. Dose-dense therapy with weekly 1-hour-paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol 1998;16:3353-61. (Pubitemid 28481632)
3. Smith RE, Brown AM, Mamounas EP, Anderson SJ, Lembersky BC, Atkins JH, et al. Randomized trial of 3-hour versus 24-hour infusion of high-dose paclitaxel in patients with metastatic or locally advanced breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-26. J Clin Oncol 1999;17:3403-11. (Pubitemid 29517907)
4. Piccart M. Taxoid compounds in breast cancer: current status and future prospects. In:Muggia FM, editor. Concepts, mechanisms, and new targets for chemotherapy. Boston, MA: Kluwer Academic Publishers; 1995. p. 185-207.
5. Mita AC, Figlin R, Mita MM. Cabazitaxel: more than a new taxane for metastatic castrate-resistant prostate cancer? Clin Cancer Res 2012;18:6574-9.
6. Sabbatini P, Sill MW, O'Malley D, Adler L, Secord AA. A phase II trial of paclitaxel poliglumex in recurrent or persistent ovarian or primary peritoneal cancer (EOC): A gynecologic oncology group study. Gynecol Oncol 2008;111:455-60.
7. Wiernik PH, Schwartz EL, Strauman JJ, Dutcher JP, Lipton RB, Paietta E. Phase I clinical and pharmacokinetic study of taxol. Cancer Res 1987;47:2486-93. (Pubitemid 17099218)
8. Cavaletti G, Bogliun G, Marzorati L, Zincone A, et al. Peripheral neurotoxicity of Taxol in patients previously treated with cisplatin. Cancer 1995;75:1141-50.
9. Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group Study. J Clin Oncol 2003;21:3194-200. (Pubitemid 46606249)
10. Neijt JP, Engelholm SA, Tuxen MK, Sorensen PG, Hansen M, Sessa C, et al. Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol 2002;18:3084-92.
11. Cavaletti G, Alberti P, Marmiroli P. Chemotherapy-induced peripheral neurotoxicity in the era of pharmacogenomics. Lancet Oncol 2011;12:1151-61.
12. Synold TW, Dussault I, Forman BM. The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nat Med 2001;7:584-90. (Pubitemid 32448326)
13. Marsh S, Somlo G, Li X, Frankel P, King CR, Shannon WD, et al. Pharmacogenetic analysis of paclitaxel transport and metabolism genes in breast cancer. Pharmacogenomics J 2007;7:362-5. (Pubitemid 47484774)
14. Baldwin RM, Owzar K, Zembutsu H, Chhibber A, Kubo M, Jiang C, et al. A genome-wide association study identifies novel loci for paclitaxel-induced sensory peripheral neuropathy in CALGB 40101. Clin Cancer Res 2012;18:5099-109.
15. Schneider BP, Li L, Miller K, et al.: Genetic associations with taxane-induced neuropathy by genome wide association study (GWAS) in E5103. J Clin Oncol 29: 2011 (suppl; abstr 1000).
16. van Zuylen LL, Verweij JJ, Sparreboom AA. Role of formulation vehicles in taxane pharmacology. Invest N Drugs 2001;19:125-41.
17. Gelderblom H, Verweij J, Nooter K, Sparreboom A. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer 2001;37:1590-8. (Pubitemid 32778603)
18. Sparreboom A, Verweij J, van der Burg ME, Loos WJ, Brouwer E, Viganò L, et al. Disposition of Cremophor EL in humans limits the potential for modulation of the multidrug resistance phenotype in vivo. Clin Cancer Res 1998;4:1937-42. (Pubitemid 28369178)
19. Rugo HS, Barry WT, Moren-Aspitia A, Lyss AP, Cirrincione C, Mayer E, et al. CALGB 40502/NCCTG N063H: Randomized phase III trial of weekly paclitaxel, compared to weekly nanoparticle albumin bound nab-paclitaxel, or ixabepilone with or without bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer [abstract]. J Clin Oncol 30, 2012 (suppl; abstr CRA1002).
20. Cancer Therapy Evaluation Program: common terminology criteria for adverse events v4.0 [Internet]. CTIS, Inc. 2004; [cited 2012 Dec 27]. Available from: http://safetyprofiler-ctep.nci.nih.gov/CTC/CTC.aspx.
21. Cella D, Peterman A, Hudgens S, Webster K, Socinski MA. Measuring the side effects of taxane therapy in oncology. Cancer 2003;98:822-31.
22. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365-76. (Pubitemid 23073154)
23. Cull A, Howat S, Greimel E, Waldenstrom AC, Arraras J, Kudelka A, et al. Development of a European Organization for Research and Treatment of Cancer questionnaire module to assess the quality of life of ovarian cancer patients in clinical trials: a progress report. Eur J Cancer 2001;37:47-53. (Pubitemid 32119359)
24. Cassidy J, Paul J, Soukop M, Habeshaw T, Reed NS, Parkin D, Kaye SB. Clinical trials of nimodipine as a potential neuroprotector in ovarian cancer patients treated with cisplatin. Cancer Chemother Pharmacol 1998;41:161-6. (Pubitemid 28096271)
25. Goel S, Goldberg GL, Kuo DY, Muggia F, Arezzo J, Mani S. Novel neurosensory testing in cancer patients treated with the epothilone B analog, ixabepilone. Ann Oncol 2008;19:2048-52.
26. Sparano JA, Wang M, Martino S, Jones V, Perez EA, Saphner T, et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 2008;358:1663-71. (Pubitemid 351549913)
27. Citron ML. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of intergroup trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003;21:1431-9. (Pubitemid 46594092)
28. Gradishar WJ. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005;23:7794-803. (Pubitemid 46657376)
29. Guan Z, Feng F, Li QL, Jiang Z, Shen Z, Yu S, et al. Randomized study comparing nab-paclitaxel with solvent-based paclitaxel in Chinese patients (pts) with metastatic breast cancer (MBC). J Clin Oncol 2007;25 (suppl; abstr 1038).
30. Gradishar WJ, Krasnojon D, Cheporov S, Makhson AN, Manikhas GM, Clawson A, et al. Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer. J Clin Oncol 2009;27:3611-9.
31. Gradishar WJ, Krasnojon D, Cheporov S, Makhson AN, Manikhas GM, Clawson A, et al. Phase II trial of nab-paclitaxel compared with docetaxel as first-line chemotherapy in patients with metastatic breast cancer: final analysis of overall survival. Clin Breast Cancer 2012;12:313-21.
32. Vahdat LT, Thomas ES, Roché HH, Hortobagyi GN, Sparano JA, Yelle L, et al. Ixabepilone-associated peripheral neuropathy: data from across the phase II and III clinical trials. Support Care Cancer 2012;20:2661-8.
33. Miles DW, Chan A, Dirix LY, Cortes J, Pivot X, Tomczak P, et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2010;28:3239-47.
34. Smith IE, Pierga JY, Biganzoli L, Cortes-Funes H, Thomssen C, Pivot X, et al. First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2251 patients. Ann Oncol 2011;22:595-602.
35. Robert NJ, Dieras V, Glaspy J, Brufsky AM, Bondarenko I, Lipatov ON, et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 2011;29:1252-60.
36. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357:2666-76.
37. Mcguire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334:1-6. (Pubitemid 26012496)
38. Spriggs DR, Brady MF, Vaccarello L, Clarke-Pearson DL, Burger RA, Mannel R, et al. Phase III randomized trial of intravenous cisplatin plus a 24- or 96-hour infusion of paclitaxel in epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2007;25:4466-71. (Pubitemid 350013853)
39. Katsumata N, Yasuda M, Takahashi F, Isonishi S, Jobo T, Aoki D, et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet 2009;374:1331-8.
40. Bookman MA, Brady MF, McGuire WP, Harper PG, Alberts DS, Friedlander M, et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a phase III trial of the Gynecologic Cancer Inter Group. J Clin Oncol 2009;27:1419-25.
41. Coleman RL, Brady WE, McMeekin DS, Rose PG, Soper JT, Lentz SS, et al. A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: A Gynecologic Oncology Group Study. Gynecol Oncol 2011;122:111-5.
42. Vasey PA, Jayson GC, Gordon A, Gabra H, Coleman R, Atkinson R, et al. Phase III Randomized trial of docetaxel-carboplatin versus paclitaxel- carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst 2004;96:1682-91. (Pubitemid 39585637)
43. Koolen SLW, Beijnen JH, Schellens JHM. Intravenous-to-oral switch in anticancer chemotherapy: a focus on docetaxel and paclitaxel. Clin Pharmacol Ther 2009;87:126-9.
44. Tije ten AJ, Synold TW, Spicer D, Verweij J, Doroshow JH, Sparreboom A. Effect of valspodar on the pharmacokinetics of unbound paclitaxel. Invest N Drugs 2003;21:291-8.
45. Lhomme C, Joly F, Walker JL, Lissoni AA, Nicoletto MO, Manikhas GM, et al. Phase III study of valspodar (PSC 833) combined with paclitaxel and carboplatin compared with paclitaxel and carboplatin alone in patients with stage iv or suboptimally debulked stage III epithelial ovarian cancer or primary peritoneal cancer. J Clin Oncol 2008;26:2674-82.
46. Schinkel AH, Smit JJ, van Tellingen O, Beijnen JH, Wagenaar E, van Deemter L, et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 1994;77:491-502. (Pubitemid 24153990)
47. Guo B, Villeneuve DJ, Hembruff SL, Kirwan AF, Blais DE, Bonin M, Parissenti AM. Cross-resistance studies of isogenic drug-resistant breast tumor cell lines support recent clinical evidence suggesting that sensitivity to paclitaxel may be strongly compromised by prior doxorubicin exposure. Breast Cancer Treat 2004;85:31-51. (Pubitemid 38437981)
48. Lilenbaum RC. Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia Group B (study 9730). J Clin Oncol 2004;23:190-6.
49. Belani CP, Ramalingam S, Perry MC, LaRocca RV, Rinaldi D, Gable PS, Tester WJ. Randomized, phase III study of weekly paclitaxel in combination with carboplatin versus standard every-3-weeks administration of carboplatin and paclitaxel for patients with previously untreated advanced non-small-cell lung cancer. J Clin Oncol 2008;26:468-73. (Pubitemid 351171701)
50. Gao G, Chu H, Zhao L, Gui T, Xu Q, Shi J. A meta-analysis of paclitaxel-based chemotherapies administered once every week compared with once every 3 weeks first-line treatment of advanced non-small-cell lung cancer. Lung Cancer 2012;76:380-6.
51. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-8. (Pubitemid 34438899)
52. Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3543-51.
53. Pignon JP, Tribodet H, Scagliotti GV, Douillard JY, Shepherd FA, Stephens RJ, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 2008;26:3552-9.
54. Douillard J-Y, Tribodet H, Aubert D, Shepherd FA, Rosell R, Ding K, et al. Adjuvant cisplatin and vinorelbine for completely resected non-small cell lung cancer: subgroup analysis of the Lung Adjuvant Cisplatin Evaluation. J Thorac Oncol 2010;5:220-8.
55. Socinski MA, Langer CJ, Okamoto I, Hon JK, Hirsh V, Dakhil SR, et al. Safety and efficacy of weekly nab(R)-paclitaxel in combination with carboplatin as first-line therapy in elderly patients with advanced non-small-cell lung cancer. Ann Oncol 2013;24;314-21.
56. Socinski MA, Bondarenko I, Karaseva NA, Makhson AM, Vynnychenko I, Okamoto I, et al. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. J Clin Oncol 2012;30:2055-62.
57. Socinski MA, Manikhas GM, Stroyakovsky DL, Makhson AN, Cheporov SVS, Orlov SV, et al. A dose finding study of weekly and every-3-week nab-Paclitaxel followed by carboplatin as first-line therapy in patients with advanced non-small cell lung cancer. J Thorac Oncol 2010;5:852-61.
58. Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006;354:34-43. (Pubitemid 43048949)
59. Scagliotti GV. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 2002;20:4285-91. (Pubitemid 35266288)
60. Kelly CM, Green MC, Broglio K, Thomas ES, Brewster AM, Valero V, et al. Phase III trial evaluating weekly paclitaxel versus docetaxel in combination with capecitabine in operable breast cancer. J Clin Oncol 2012;30:930-935.
61. Ibrahim NK, Buzdar AU, Valer V, Dhingra K, Willey J, Hortobagyi GN. Phase I study of vinorelbine and paclitaxel by 3-hour simultaneous infusion with and without granulocyte colony-stimulating factor support in metastatic breast carcinoma. Cancer 2001;91:664-71. (Pubitemid 32173289)
62. Ibrahim NK, Rahman Z, Valero V, Murray JL, Frye D, Hortobagyi GN. Phase I study of vinorelbine and docetaxel with granulocyte colony-stimulating factor support in the treatment of metastatic breast cancer. Cancer Invest 2002;20:29-37. (Pubitemid 34151057)
63. Sewak S, Chachoua A, Hamilton A, Taneja S, Lee J, Utate M, et al. A phase I study of paclitaxel, estramustine phosphate and vinorelbine (Pacl-E-Vin) in advanced malignancies: triple tubulin targeting. Anticancer Drugs 2003;14:67-72. (Pubitemid 36177356)
64. Budman DR, Weiselberg L, O'Mara V. Re: Severe neurotoxicity in vinorelbine-paclitaxel combinations. J Natl Cancer Inst 1997;89:87-8.
65. Khrapunovich-Baine M, Menon V, Verdier-Pinard P, Smith AB, Angeletti RH, Fiser A, et al. Distinct pose of discodermolide in taxol binding pocket drives a complementary mode of microtubule stabilization. Biochemistry 2009;48:11664-77.
66. Mielke S, Sparreboom A, Mross K. Peripheral neuropathy: a persisting challenge in paclitaxel-based regimes. Eur J Cancer 2006;42:24-30. (Pubitemid 41814529)
67. Desai N, Trieu V, Yao Z, Louie L, Ci S, Yang A, et al. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of Cremophor- free, albumin-bound paclitaxel, ABI-007, compared with Cremophor-based paclitaxel. Clin Cancer Res 2006;12:1317-24. (Pubitemid 43342524)
68. Riou JF, Naudin A, Lavelle D. Effects of Taxotere on murine and human cell lines. Biochem Biophys Res Commun 1992;187:164-70.
69. Wils P, Phung-Ba V, Warnery A, Lechardeur D, Raeissi S, Hidalgo IJ, et al. Polarized transport of docetaxel and vinblastine mediated by P-glycoprotein in human intestinal epithelial cell monolayers. Biochem Pharmacol 1994;48:1528-30. (Pubitemid 24318161)
70. Kruijtzer CMF, Beijnen JH, Schellens JHM. Improvement of oral drug treatment by temporary inhibition of drug transporters and/or cytochrome P450 in the gastrointestinal tract and liver: an overview. Oncologist 2002;7:516-30. (Pubitemid 36009000)
71. Bardelmeijer HA, Beijnen JH, Brouwer KR, Rosing H, Nooijen WJ, Schellens JHM, et al. Increased oral bioavailability of paclitaxel by GF120918 in mice through selective modulation of P-glycoprotein. Clin Cancer Res 2000;6:4416-21.
72. Marre F, Sanderink G, de Sousa G, Gaillard C, Martinet M, Rahmani R. Hepatic biotransformation of docetaxel (Taxotere) in vitro: involvement of the CYP3A subfamily in humans. Cancer Res 1996;56:1296-302. (Pubitemid 26080972)
73. Bardelmeijer H, Ouwehand M, Buckle T, Huisman MT, Schellens JHM, Beijnen JH, et al. Low systemic exposure of oral docetaxel in mice resulting from extensive first-pass metabolism is boosted by ritonavir. Cancer Res 2002;62:6158-64. (Pubitemid 35244466)
74. Francis P, Rowinsky E, Schneider J, Hakes T, Hoskins W, Markman M. Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: a Gynecologic Oncology Group pilot Study. J Clin Oncol 1995;13:2961-7.
75. Krasner CN, Seiden MV, Fuller AF, Roche M, et al. Pharmacokinetic analysis of an all intraperitoneal carboplatin and paclitaxel regimen in ovarian cancer patients demonstrates favorable systemic bioavailability of both agents. J Clin Oncol 2006;24 (suppl; abstr 5008).
76. Morgan RJ, Doroshow JH, Synold T, Lim D, Shibata S, Margolin K, et al. Phase I trial of intraperitoneal docetaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavity: dose-limiting toxicity and pharmacokinetics. Clin Cancer Res 2003;9:5896-901. (Pubitemid 38018073)
77. Miyamoto K, Shimada T, Sawamoto K, Sai Y, Yonemura Y. Disposition kinetics of taxanes in peritoneal dissemination. Gastroenterol Res Pract 2012;11:1-9.